BR9915315A - Formas cristalinas de 3-(2,4-diclorobenzil)-2metil-n-(pentilsulfonil)-3h-ben zimidazol-5-carboxamida - Google Patents
Formas cristalinas de 3-(2,4-diclorobenzil)-2metil-n-(pentilsulfonil)-3h-ben zimidazol-5-carboxamidaInfo
- Publication number
- BR9915315A BR9915315A BR9915315-7A BR9915315A BR9915315A BR 9915315 A BR9915315 A BR 9915315A BR 9915315 A BR9915315 A BR 9915315A BR 9915315 A BR9915315 A BR 9915315A
- Authority
- BR
- Brazil
- Prior art keywords
- pentylsulfonyl
- dichlorobenzyl
- carboxamide
- crystalline forms
- methyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/08—Radicals containing only hydrogen and carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/10—Radicals substituted by halogen atoms or nitro radicals
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Reproductive Health (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Patente de Invenção: <B>"FORMAS CRISTALINAS DE 3-(2,4-DICLOROBENZIL)-2-METIL-N-(PENTILSULFONIL)-3H-BEN ZIMIDAZOL-5-CARBOXAMIDA"<D>. 3-(2,4-diclorobenzil)-2-metil-N-(pentilsulfonil)-3H-benzimidazol-5-carb oxamida, um composto tendo atividade hipoglicêmica ou efeito inibidor PDE5, tem três forma cristalina que são distinguíveis por seus valores de difração em pó de raio X. A forma cristalina mais cristalograficamente estável é útil como uma substância droga para medicamentos. Uma outra forma cristalina pode ser eficientemente purificada por cristalização, uma vez que ela forma maiores cristais e pode ser muito facilmente isolada por filtração. Assim, esta forma cristalina é útil para purificação e 3-(2,4-diclorobenzil)-2-metil-N-(pentilsulfonil)-3H-benzimidazol-5-carb oxamida.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP32402698 | 1998-11-13 | ||
PCT/JP1999/006296 WO2000029383A1 (fr) | 1998-11-13 | 1999-11-11 | Formes cristallines du 3-(2,4-dichlorobenzyl)-2-methyl-n-(pentylsulfonyl)-3h-benzimidazole-5-carboxamide |
Publications (1)
Publication Number | Publication Date |
---|---|
BR9915315A true BR9915315A (pt) | 2001-08-07 |
Family
ID=18161331
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR9915315-7A BR9915315A (pt) | 1998-11-13 | 1999-11-11 | Formas cristalinas de 3-(2,4-diclorobenzil)-2metil-n-(pentilsulfonil)-3h-ben zimidazol-5-carboxamida |
Country Status (11)
Country | Link |
---|---|
US (1) | US6703410B1 (pt) |
EP (2) | EP1132087A4 (pt) |
KR (1) | KR20010080444A (pt) |
CN (1) | CN1136196C (pt) |
AU (1) | AU764594B2 (pt) |
BR (1) | BR9915315A (pt) |
CA (1) | CA2350520A1 (pt) |
HK (1) | HK1040078B (pt) |
HU (1) | HUP0104029A3 (pt) |
RU (1) | RU2228931C2 (pt) |
WO (2) | WO2000028991A1 (pt) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1132087A4 (en) | 1998-11-13 | 2002-06-26 | Fujisawa Pharmaceutical Co | MEDICINE AGAINST POLYCYSTIC OVARY SYNDROME |
WO2000039099A1 (fr) | 1998-12-24 | 2000-07-06 | Fujisawa Pharmaceutical Co., Ltd. | Derives de benzimidazole |
CA2441798C (en) * | 2001-03-27 | 2009-10-20 | Sumitomo Pharmaceuticals Company, Limited | Crystalline isoxazole derivative and medical preparation thereof |
BR0307595A (pt) * | 2002-02-07 | 2005-02-01 | Pfizer | Uso de inibidores de pde5 tal como sildenafil no tratamento de sìndrome de ovário policìstico |
EP1581247A4 (en) * | 2002-12-11 | 2007-09-12 | Amylin Pharmaceuticals Inc | METHODS AND COMPOSITIONS FOR TREATING STEIN-LEVENTHAL SYNDROME |
US7781478B2 (en) | 2004-07-14 | 2010-08-24 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
US20080194860A1 (en) * | 2006-10-10 | 2008-08-14 | Transform Pharmaceuticals, Inc. | Novel crystal of (s)-(+)-2-(2-chlorophenyl)-2-hydroxy-ethyl carbamate |
MX2012001240A (es) * | 2009-07-30 | 2012-06-12 | Aestus Therapeutics Inc | Metodo para el tratamiento de dolor neuropatico con agonistas del derivado de bencimidazol de ppargamma. |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EE04310B1 (et) | 1995-04-21 | 2004-06-15 | Neurosearch A/S | Bensimidasooli ühendid, neid ühendeid sisaldavad farmatseutilised kompositsioonid ja nende kasutamine |
IL118474A (en) * | 1995-06-01 | 2001-08-08 | Sankyo Co | Benzimideol derivatives and pharmaceutical preparations containing them |
JPH09165371A (ja) * | 1995-10-09 | 1997-06-24 | Sankyo Co Ltd | 複素環化合物を含有する医薬 |
EA002357B1 (ru) * | 1995-12-28 | 2002-04-25 | Фудзисава Фармасьютикал Ко., Лтд. | Производные бензимидазола |
AU4400597A (en) * | 1996-10-08 | 1998-05-05 | Fujisawa Pharmaceutical Co., Ltd. | Indole derivatives |
JP3268242B2 (ja) * | 1996-11-14 | 2002-03-25 | 三共株式会社 | 縮合複素環化合物を含有する医薬 |
TW453999B (en) * | 1997-06-27 | 2001-09-11 | Fujisawa Pharmaceutical Co | Benzimidazole derivatives |
CN1150167C (zh) * | 1998-04-06 | 2004-05-19 | 藤泽药品工业株式会社 | 吲哚衍生物 |
EP1132087A4 (en) * | 1998-11-13 | 2002-06-26 | Fujisawa Pharmaceutical Co | MEDICINE AGAINST POLYCYSTIC OVARY SYNDROME |
-
1999
- 1999-11-10 EP EP99972100A patent/EP1132087A4/en not_active Withdrawn
- 1999-11-10 WO PCT/JP1999/006267 patent/WO2000028991A1/ja not_active Application Discontinuation
- 1999-11-11 AU AU11783/00A patent/AU764594B2/en not_active Ceased
- 1999-11-11 HU HU0104029A patent/HUP0104029A3/hu unknown
- 1999-11-11 CN CNB998143251A patent/CN1136196C/zh not_active Expired - Fee Related
- 1999-11-11 EP EP99972205A patent/EP1138674A4/en not_active Withdrawn
- 1999-11-11 US US09/831,082 patent/US6703410B1/en not_active Expired - Fee Related
- 1999-11-11 KR KR1020017006041A patent/KR20010080444A/ko not_active Application Discontinuation
- 1999-11-11 CA CA002350520A patent/CA2350520A1/en not_active Abandoned
- 1999-11-11 BR BR9915315-7A patent/BR9915315A/pt not_active IP Right Cessation
- 1999-11-11 WO PCT/JP1999/006296 patent/WO2000029383A1/ja not_active Application Discontinuation
- 1999-11-11 RU RU2001116105/04A patent/RU2228931C2/ru not_active IP Right Cessation
-
2002
- 2002-02-26 HK HK02101470.5A patent/HK1040078B/zh not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
EP1132087A4 (en) | 2002-06-26 |
EP1138674A4 (en) | 2002-08-21 |
EP1132087A1 (en) | 2001-09-12 |
WO2000029383A1 (fr) | 2000-05-25 |
EP1138674A1 (en) | 2001-10-04 |
CN1330641A (zh) | 2002-01-09 |
US6703410B1 (en) | 2004-03-09 |
HUP0104029A3 (en) | 2002-07-29 |
HUP0104029A2 (hu) | 2002-05-29 |
RU2228931C2 (ru) | 2004-05-20 |
AU1178300A (en) | 2000-06-05 |
CA2350520A1 (en) | 2000-05-25 |
KR20010080444A (ko) | 2001-08-22 |
AU764594B2 (en) | 2003-08-21 |
HK1040078A1 (en) | 2002-05-24 |
CN1136196C (zh) | 2004-01-28 |
HK1040078B (zh) | 2004-07-09 |
WO2000028991A1 (fr) | 2000-05-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO306464B1 (no) | Benzimidazolforbindelser, farmasöytiske preparater som omfatter slike forbindelser, samt anvendelse av forbindelsene for fremstilling av medikamenter | |
NO20056007L (no) | Dobbel NK1/NK3 antagonister for behandling av schizofreni | |
ATE197038T1 (de) | N-aroyl-glycin-hydroxamsäure-derivate und verwandte verbindungen | |
GB0206860D0 (en) | Compounds | |
DE60325074D1 (de) | Kristall für ein orales, festes arzneimittel, und ein orales, festes arnzeimittel zur behandlung von dysurie, das diesen enthält | |
AU2804400A (en) | Phenyl urea and phenyl thiourea derivatives as orexin receptor antagonists | |
WO2003068753A1 (fr) | Composes a noyau fusionne contenant n-carbamoyle azote et medicaments contenant ces composes comme ingredients actifs | |
CA2338220A1 (en) | Substituted imidazoles having cytokine inhibitory activity | |
AU2003270199A1 (en) | Urea compounds active as vanilloid receptor antagonists for the treatment of pain | |
JO2273B1 (en) | Dihydro-benzo derivatives [B] [1.4] di-azin-2-one | |
BR9915315A (pt) | Formas cristalinas de 3-(2,4-diclorobenzil)-2metil-n-(pentilsulfonil)-3h-ben zimidazol-5-carboxamida | |
ATE102930T1 (de) | Heterozyklische verbindungen, deren herstellung und medikamente diese enthaltend. | |
DK0687177T3 (da) | Anvendelse af lamotrigin ved fremstilling af lægemidler til behandling af AIDS-relaterede nervesygdomme | |
DK0765320T3 (da) | Benzimidazolonderivater med central dopaminerg aktivitet | |
IL163951A0 (en) | New heterocyclic compounds process for their preparation and pharmaceutical compositions containing them and their use in medicine | |
BR9910058A (pt) | Compostos azapolicìclicos aril-condensados | |
WO2004041802A8 (en) | 4(phenyl-piperazinyl-methyl) benzamide derivatives and their use for the treatment of pain or gastrointestinal disorders | |
BR9503572A (pt) | Composto composiçao farmaceutica e método de tratamento ou prevençao de uma doença | |
DE60221813D1 (de) | Thiazolopyrimidinderivate und deren verwendung als antagonisten des cx3cr1 rezeptors | |
ATE266029T1 (de) | Substituierte pyrrolobenzimidazolderivate zur entzündungshemmung | |
BR0207102A (pt) | Forma cristalina, composição farmacêutica, uso de uma forma cristalina, e, método para a prevenção ou o tratamento de doença | |
WO2005053702A3 (en) | Anti-inflammatory agents | |
ITMI922742A0 (it) | Composti ad attivita' terapeutica utili per il trattamento di malattieconnesse ad una carenza di glutatione, procedimento per la loro preparazione e composizioni farmaceutiche che li contengono. | |
ATE405275T1 (de) | Kombinationsarzneimittel aus r,r-formoterol und ciclesonide | |
ATE269858T1 (de) | Kristallines oder kristallisiertes säureadditionssalz von losartan und verfahren zur reinigung von losartan |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B25A | Requested transfer of rights approved |
Owner name: DAICEL CHEMICAL INDUSTRIES, LTD. (JP) , YAMANOUCHI Free format text: TRANSFERIDO POR FUSAO DE: FUJISAWA PHARMACEUTICAL CO., LTD. |
|
B25D | Requested change of name of applicant approved |
Owner name: DAICEL CHEMICAL INDUSTRIES, LTD. (JP) , ASTELLAS P Free format text: ALTERADO DE: YAMANOUCHI PHARMACEUTICAL CO., LTD. |
|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 7A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 1946 DE 22/04/2008. |